| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Technology Officer | Chief Operating Officer
1 company
Kurtoglu Metin serves as a Chief Technology Officer at RNAC. Across recent SEC filings that breaks down to 0 buys and 14 sells. Those positions are worth an estimated $1.0M at current prices.
Historically, Kurtoglu Metin's trades have earned a strong insider score of 80/100 across 10 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +59.9%.
The biggest single holding is RNAC (~$1.0M) as Chief Technology Officer. The recent filings there lean toward selling, a net 139,596 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 6, 2025 | RNAC Cartesian Therapeutics, Inc. | Chief Technology Officer | Sell | 4,875 | $16.78 | $81,790.38 | -7.3% | -42.7% | -60.1% | |
| Dec 10, 2024 | RNAC Cartesian Therapeutics, Inc. | Chief Technology Officer | Sale+OE | 13,664 | $25.26 | $345,133.86 | -21.1% | -21.5% | -65.6% | |
| Nov 21, 2024 | RNAC Cartesian Therapeutics, Inc. | Chief Technology Officer | Sale+OE | 38,689 | $16.78 | $649,029.56 | -43.1% | +16.4% | -56.4% | |
| Nov 18, 2024 | RNAC Cartesian Therapeutics, Inc. | Chief Technology Officer | Sale+OE | 82,368 | $17.46 | $1,438,037.68 | -61.7% | +5.1% | -59.0% |